Søk Finn patenter, varemerker og design i Norge Nøkkelinformasjon Databasen er sist oppdatert 2017.08.12 12:14:00 Tittel Status Hovedstatus Detaljstatus Patentnummer Europeisk (EP) publiserings nummer K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY I kraft 2014.06.23 EP patent gjort gjeldende i Norge 2014.06.23 EP patent besluttet gjeldende i Norge NO/EP2121989 EP2121989 EP inngitt 2008.03.11 EP søknadsnummer 08742061.8 EP meddelt 2014.01.22 Prioritet Sakstype 2007.03.13, 906943 P Europeisk Løpedag 2008.03.11 Utløpsdato 2028.03.11 Allment tilgjengelig 2009.11.25 Validert i Norge 2014.06.23 Innehaver Oppfinner Fullmektig Lenke til European patent Register Patentfamilie Amgen Inc. () FREEMAN, Daniel () Onsagers AS (NO) Informasjon i saken, dokumenter og patentfamilie Se i Espacenet Sammendrag og figur Se forsidefigur og sammendrag i Espacenet Klasser IPC-klasse C12Q 1/68 G01N 33/574 Søker Innehaver Innehaver i EP:
Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 Oppfinner FREEMAN, Daniel 942 Grayrock Street Newbury Park, CA 91320 JUAN, Todd 4629 Calle San Juan Newbury Park, CA 91320 RADINSKY, Robert 3574 Lang Ranch Parkway Thousand Oaks, CA 91362 Fullmektig Fullmektig i Norge: Onsagers AS Se mer Postboks 1813 Vika 0123 OSLO NO ( OSLO kommune, OSLO fylke ) Org.nummer: 934603729 Referanse på sak: P23749NOEP Fullmektig i EP: Grünecker Patent- und Rechtsanwälte PartG mbb Leopoldstraße 4 80802 München DE Prioritet 2007.03.13, 906943 P Anførte dokumenter WO-A-2007/001868 (B1/EP) EBERHARD D A ET AL: "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 23, no. 25, 1 September 2004 (2004-09-01), pages 5900-5909, XP002400936 ISSN: 0732-183X (B1/EP) PAO W ET AL: "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib" PLOS MEDICINE 2005, vol. 2, no. 1, 2005, pages 0057-0061, XP002400935 ISSN: 1549-1277 1549-1676 (B1/EP) LIÈVRE ASTRID ET AL: "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer." CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 (2006-04-15), pages 3992-3995, XP002400937 ISSN: 0008-5472 (B1/EP) BENVENUTI SILVIA ET AL: "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies" 20070315, 15 March 2007 (2007-03-15), XP002491315 (B1/EP)
KIRK REBECCA: "Genetics: In colorectal cancer, not all KRAS mutations are created equal.", NATURE REVIEWS. CLINICAL ONCOLOGY JAN 2011, vol. 8, no. 1, January 2011 (2011-01), page 1, XP009166871, ISSN: 1759-4782 (B1/EP) FRIDAY ET AL: "K-ras as a target for cancer therapy" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 (2005-11-25), pages 127-144, XP005204727 ISSN: 0304-419X (B1/EP) CARAGLIA MICHELE ET AL: "EGF-R small inhibitors and anti-egf-r antibodies: advantages and limits of a new avenue in anticancer therapy." RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY JUN 2006, vol. 1, no. 2, June 2006 (2006-06), pages 209-222, XP009104857 ISSN: 1574-8928 (B1/EP) CHUA YU JO ET AL: "Panitumumab" DRUGS OF TODAY, vol. 42, no. 11, November 2006 (2006-11), pages 711-719, XP002493245 ISSN: 1699-3993 (B1/EP) M C Garassino ET AL: "Effect of tumor-specific KRAS mutational status on impact of anti-egfr therapy in non-small cell lung cancer (NSCLC)", J. Clin. Oncol. 28: 15s (suppl; abstr. 7564), 1 January 2010 (2010-01-01), XP055052539, [retrieved on 2013-02-06] (B1/EP) AMADO RAFAEL G ET AL: "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 10, 1 April 2008 (2008-04-01), pages 1626-1634, XP009104317 ISSN: 0732-183X (B1/EP) AMADO RAFAEL G ET AL: "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 10, 1 April 2008 (2008-04-01), pages 1626-1634, XP009104317 ISSN: 0732-183X (B1) BENVENUTI SILVIA ET AL: "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies" 20070315, 15 March 2007 (2007-03-15), XP002491315 (B1) CARAGLIA MICHELE ET AL: "EGF-R small inhibitors and anti-egf-r antibodies: advantages and limits of a new avenue in anticancer therapy." RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY JUN 2006, vol. 1, no. 2, June 2006 (2006-06), pages 209-222, XP009104857 ISSN: 1574-8928 (B1) CHUA YU JO ET AL: "Panitumumab" DRUGS OF TODAY, vol. 42, no. 11, November 2006 (2006-11), pages 711-719, XP002493245 ISSN: 1699-3993 (B1) EBERHARD D A ET AL: "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 23, no. 25, 1 September 2004 (2004-09-01), pages 5900-5909, XP002400936 ISSN: 0732-183X (B1) WO-A-2007/001868 (B1) KIRK REBECCA: "Genetics: In colorectal cancer, not all KRAS mutations are created equal.", NATURE REVIEWS. CLINICAL ONCOLOGY JAN 2011, vol. 8, no. 1, January 2011 (2011-01), page 1, XP009166871, ISSN: 1759-4782 (B1) LIÈVRE ASTRID ET AL: "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer." CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 (2006-04-15), pages 3992-3995, XP002400937 ISSN: 0008-5472 (B1) M C Garassino ET AL: "Effect of tumor-specific KRAS mutational status on impact of anti-egfr therapy in non-small cell lung cancer (NSCLC)", J. Clin. Oncol. 28: 15s (suppl; abstr. 7564), 1 January 2010 (2010-01-01), XP055052539, [retrieved on 2013-02-06] (B1) PAO W ET AL: "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib" PLOS MEDICINE 2005, vol. 2, no. 1, 2005, pages 0057-0061, XP002400935 ISSN: 1549-1277 1549-1676 (B1) FRIDAY ET AL: "K-ras as a target for cancer therapy" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 (2005-11-25), pages 127-144, XP005204727 ISSN: 0304-419X (B1) Lisens Pant Klage til Klagenemnda Administrativ prøving Innsigelse Protest / Oppreisning Sakshistorikk Statushistorie Hovedstatus Beslutningsdato, detaljstatus
Hovedstatus Beslutningsdato, detaljstatus 2014.06.23 EP patent gjort gjeldende i Norge 2014.06.23 EP patent besluttet gjeldende i Norge 2014.04.22 EP under behandling 2014.04.28 Forespørsel om å gjøre EP patent gyldig er mottatt Korrespondanse Dato Type korrespondanse Journal beskrivelse 2016.11.02 Innkommende EP Publiseringsdokument fra EPO 2014.11.26 Innkommende EP Publiseringsdokument fra EPO 2014.07.03 Utgående EP Registreringsbrev 2014.06.02 Utgående EP Batch Påminnelse om ikke betalt årsavgift (3331) 2014.05.07 Utgående Betalt gammel stats for årsavgift 2014.05.05 Utgående Betalt gammel satsa for årsavgift 2014.04.22 Innkommende, AR67999249 Søknadsskjema Patent 2014.01.22 Innkommende EP Publiseringsdokument fra EPO Informasjon om ikke tilgjengelige dokumenter Betaling Til betaling: Betalingshistorikk: Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status Årsavgift 10. avg. år (EP) 2017.03.09 3200,0 CPA GLOBAL LIMITED Årsavgift 9. avg. år (EP) 2016.03.09 2850 Computer Patent Årsavgift 8. avg. år (EP) 2015.03.10 2550 Computer Patent Årsavgift 7. avg. år (EP) 2014.07.15 2640 Bryn Aarflot AS 31405892 2014.05.13 6400 Onsagers AS Betalt [Kreditering] Årsavgift 7. avg. år (EP) 2014.05.07-2400 Computer Patent Årsavgift 7. avg. år (EP) 2014.04.25 2400 Computer Patent Kreditert Betalt Denne oversikten kan mangle informasjon, spesielt for eldre saker, internasjonale varemerker og internasjonale design. Publikasjon(er) Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter) Oversettelse av europeisk patentskrift Norsk Patenttidende (ved meddelelse) Lenker til publikasjoner (ikke søkbare tekstdokumenter) B1/EP
Hva betyr A1, B, B1, C osv?